alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › glucagon-like

glucagon-like

285 studies tagged glucagon-like, dated 1994-05-01 to 2026-10-30. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration 2026-10-30
  2. Beyond Glycemic Control: The Pleiotropic Role of GLP-1RAs and Melatonin in Combating Neuroinflammation and Mitochondrial Dysfunction 2026-10-28
  3. PFKFB3 inhibition restores β-cell responsiveness to acetylcholine in a 3xTg-AD pancreatic tissue-slice model 2026-10-07

Studies

285 studies carry this tag.

Date range

1994 to 2026

Top journals

  • International journal of molecular sciences 10
  • Neuropharmacology 10
  • Journal of Alzheimer's disease : JAD 9
  • European journal of pharmacology 8
  • Neurobiology of aging 6

177 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of pathology 2018-04-02 Drug development

    Alzheimer's disease (AD) is a devastating neurological disorder that still lacks an effective treatment, and this has stimulated an intense pursuit of disease-modifying therapeutics.

  2. Inflammation, insulin signaling and cognitive function in aged APP/PS1 mice

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain, behavior, and immunity 2018-03-29 Drug development

    Cognitive dysfunction and neuroinflammation are typical in Alzheimer's disease (AD), but are also associated with normal aging, albeit less severely.

  3. Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Diabetes & metabolic syndrome 2018-03-16 Drug development

    Glucagon-like peptide-1 (GLP-1) is a 30 amino acid long peptide hormone derived from the proglucagon gene and secreted in the distal small intestine when food enters the duodenum.

  4. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. European journal of pharmacology 2018-03-15 Drug development

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which there is no cure.

  5. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Hippocampus 2018-03-05 Drug development

    Type 2 diabetes mellitus (T2DM) is an important risk factor for Alzheimer's disease (AD).

  6. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2018-01-31 Drug development

    Type 2 diabetes is a risk factor for several chronic neurodegenerative disorders such as Alzheimer's or Parkinson's disease.

  7. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Neurology 2018-01-29 Risk factors

    Considerable overlap has been identified in the risk factors, comorbidities and putative pathophysiological mechanisms of Alzheimer disease and related dementias (ADRDs) and type 2 diabetes mellitus (T2DM), two of the most pressing epidemics of our time.

  8. Therapeutic potential of spinal GLP-1 receptor signaling

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Peptides 2018-01-09 Drug development

    GLP-1 signaling pathway has been well studied for its role in regulating glucose homeostasis, as well as its beneficial effects in energy and nutrient metabolism.

  9. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurobiology of aging 2017-12-19 Drug development

    Modulation of insulin-dependent signaling is emerging as a valuable therapeutic tool to target neurodegeneration.

  10. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Scientific reports 2017-12-13 Drug development

    There are fewer than normal glucose transporters at the blood-brain barrier (BBB) in Alzheimer's disease (AD).

  11. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biochemical and biophysical research communications 2017-11-22 Drug development

    Type 2 diabetes mellitus (T2DM) has been identified as a high risk factor for Alzheimer's disease (AD).

  12. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2017-11-22 Drug development

    Alzheimer's disease (AD), characterized by the aggregation of amyloid-β (Aβ) protein and neuroinflammation, is the most common neurodegenerative disease globally.

  13. Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Scientific Reports 2017-11-17 Drug development

    Growing evidence suggests that agonists of glucagon-like peptide (GLP-1) receptor exert neuroprotective and neurorestorative effects across a range of experimental models of neuronal degeneration, and, recently, a pilot clinical trial of Liraglutide in Alzheimer’s disease patients showed improvements in cerebral glucose consumption that signifies disease progression.

  14. Neurotrophic and Neuroregenerative Effects of GH/IGF1

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2017-11-17 Costs and economics

    Although strong findings have shown the positive effects of GH/IGF-1 administration on neuroregeneration in animal models, a very limited number of clinical studies have been conducted in humans.

  15. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cell transplantation 2017-09-01 Drug development

    Molecular communications in the gut-brain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging.

  16. Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Pharmaceutical research 2017-06-06 Drug development

    Type 2 diabetes mellitus (T2DM) is a complex, chronic and progressive metabolic disease, which is characterized by relative insulin deficiency, insulin resistance, and high glucose levels in blood.

  17. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecular neurobiology 2017-06-02 Drug development

    Chronic Ex-4 treatment attenuated peripheral features of T2D in GK rats, including hyperglycemia and insulin resistance.

  18. Insulin resistance and exendin-4 treatment for multiple system atrophy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain : a journal of neurology 2017-05-01 Drug development

    We here tested the hypothesis that multiple system atrophy is associated with brain insulin resistance and showed increased expression of the key downstream messenger insulin receptor substrate-1 phosphorylated at serine residue 312 in neurons and oligodendrocytes in the putamen of patients with multiple system atrophy.

  19. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2017-02-20 Drug development

    The incretins glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are growth factors that have shown neuroprotective effects in animal models of Parkinson's and Alzheimer's disease.

  20. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Trends in endocrinology and metabolism: TEM 2016-10-27 Drug development

    Glucagon-like peptide-1 (GLP-1) is released in response to meals and exerts important roles in the maintenance of normal glucose homeostasis.

  21. High fat diet induces brain insulin resistance and cognitive impairment in mice

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Biochimica et biophysica acta. Molecular basis of disease 2016-10-19 Prevention trials

    High fat diet-induced obesity is associated with insulin resistance (IR) and other chronic, diet related illnesses, including dementia.

  22. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecular neurobiology 2016-10-03 Drug development

    Glucagon-like peptide-1 (GLP-1) is an incretin hormone shown to be active in the treatment of type-2 diabetes (T2D) and has also been shown as efficacious in Alzheimer's disease (AD).

  23. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. PLoS ONE 2016-07-15 Drug development

    One of the major histopathological hallmarks of Alzheimer's disease (AD) is cerebral deposits of extracellular β-amyloid peptides.

  24. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in aging neuroscience 2016-05-24 Drug development

    In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD).

  25. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European journal of pharmacology 2016-04-27 Drug development

    Type 2 diabetes mellitus is a risk factor for Alzheimer's disease (AD).

  26. Diabetes and Alzheimer's disease crosstalk

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience and biobehavioral reviews 2016-03-09 End-of-life care

    Despite intensive research efforts over the past few decades, the mechanisms underlying the etiology of sporadic Alzheimer's disease (AD) remain unknown.

  27. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drug discovery today 2016-02-03 Drug development

    Growing evidence suggests that agonists of the glucagon-like peptide 1 (GLP-1) receptor provide neuroprotection across a range of experimental models of Parkinson's disease (PD) and, recently, a small proof-of-concept, open-label human trial of exenatide in the treatment moderate severity PD appeared to show persistent improvements in motor and cognitive function.

  28. Metformin Facilitates Amyloid-β Generation by β- and γ-Secretases via Autophagy Activation

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer's disease : JAD 2016 Drug development

    The evidence of strong pathological associations between type 2 diabetes and Alzheimer's disease (AD) has increased in recent years.

  29. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Reviews in the neurosciences 2016-01-01 Drug development

    Glucose-dependent insulinotropic polypeptide (GIP) is a member of the incretin hormones and growth factors.

  30. Brain-derived neurotrophic factor and its clinical implications

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Archives of medical science : AMS 2015-12-11 Risk factors

    Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal survival and growth, serves as a neurotransmitter modulator, and participates in neuronal plasticity, which is essential for learning and memory.

  31. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CNS drugs 2015-12-01 Drug development

    The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades.

  32. Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecular and cellular neurosciences 2015-11-27 Drug development

    Type 2 diabetes (T2D) is a high risk factor for Alzheimer's disease (AD).

  33. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain research 2015-10-11 Drug development

    The incretins glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are growth factors with neuroprotective properties.

  34. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. European journal of pharmacology 2015-09-16 Drug development

    Recent studies suggest a possible link between type 2 diabetes and Alzheimer's disease (AD).

  35. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of neurochemistry 2015-08-11 Drug development

    Increasing evidence has shown that type 2 diabetes (T2D) is a risk factor for Alzheimer's disease.

  36. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Behavioural brain research 2015-07-20 Drug development

    Type 2 diabetes is a risk factor for Alzheimer's disease (AD).

  37. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience 2015-07-02 Drug development

    Glucagon-like peptide 1 (GLP-1) is a growth factor.

  38. Emerging links between type 2 diabetes and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. World journal of diabetes 2015-06-01 Drug development

    Type 2 diabetes mellitus and Alzheimer's disease are both associated with increasing age, and each increases the risk of development of the other.

  39. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. World journal of diabetes 2015-06-01 Drug development

    Long-acting glucagon-like peptide-1 (GLP-1) analogues marketed for type 2 diabetes (T2D) treatment have been showing positive and protective effects in several different tissues, including pancreas, heart or even brain.

  40. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Clinical interventions in aging 2015-03-10 Drug development

    The aim of this paper is to provide a comprehensive review of the epidemiological evidence linking type 2 diabetes mellitus and its related conditions, including obesity, hyperinsulinemia, and metabolic syndrome, to Alzheimer's disease (AD).

  41. Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Alzheimer s Disease 2015-02-06 Genetics

    Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI).

  42. Saxagliptin: a novel antiparkinsonian approach

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2015-02-01 Drug development

    The emergence of glucagon-like peptide-1 as a crucial contender in modifying neurodegenerative diseases in the preclinical studies has instigated interest in investigating the antiparkinsonian effect of dipeptidyl peptidase (DPP)-4 inhibition.

  43. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cardiovascular diabetology 2015-01-13 Drug development

    Advanced glycation end products (AGEs) consist of heterogenous group of macroprotein derivatives, which are formed by non-enzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids, and whose process has progressed at an accelerated rate under diabetes.

  44. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Alzheimer's disease : JAD 2015-01-01 Drug development

    Recent studies indicate that glucagon-like peptide 1 (GLP-1) receptor agonists, currently used in the management of type 2 diabetes, exhibit neurotrophic and neuroprotective effects in amyloid-β (Aβ) toxicity models of Alzheimer's disease (AD).

  45. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2014-08-08 Drug development

    Type 2 diabetes is a risk factor for developing Alzheimer's disease (AD).

  46. Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in endocrinology 2014-07-08 Drug development

    Type 2 diabetes (T2D) and Alzheimer disease (AD) are two major health issues nowadays.

  47. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biochemical Society transactions 2014-04-01 Drug development

    Recently, it has been shown that in patients with AD (Alzheimer's disease) and, to some degree, in patients with PD (Parkinson's disease) insulin signalling is impaired.

  48. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of endocrinology 2014-03-07 Drug development

    The incretin hormone glucagon-like peptide 1 (GLP-1) has many effects in the body.

  49. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Progress in neurobiology 2014-02-28 Drug development

    Insulin and Insulin Growth Factor-1 (IGF-1) play a major role in body homeostasis and glucose regulation.

  50. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience 2014-02-27 Drug development

    Alzheimer's disease (AD) is a progressive and degenerative disorder accompanied by cognitive impairment, but effective strategies against AD are currently not available.

From across this tag

7 of the 285 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.

All topic tags with their study counts